Impaired – Talk Bio

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

1 month ago talkbio0Tagged Capitalization, clinical-stage biopharma, development aspects, exophthalmos producing substance, financial results, Impaired, Market, net loss, Nkarta, Operating expenses, Q3, research

Nkarta; Q3 2025 financial results; net loss; operating expenses; EPS; research and development; impairment; market capitalization; clinical-stage biopharma; corporate highlights

Curtain Closes on Takeda’s Cell Therapy Efforts

2 months ago talkbio0Tagged Biological Factors, Cell Therapy, Gamma/Delta T-Lymphocyte, Impaired, research discontinuation, strategic shift, Takeda

Takeda; cell therapy; research discontinuation; impairment loss; gamma delta T-cell; strategic shift; biopharmaceuticals

Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge

10 months ago talkbio0Tagged charge amounts, Clinical Trials, Escherichia coli, Failure (biologic function), Impaired, Johnson & Johnson, Phase 3, sanofi, Vaccines

Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation

AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset

10 months ago talkbio0Tagged Alexion, AstraZeneca, charge amounts, Complement Inactivating Agents, drug discontinuation, Drug Industry, Impaired, Vemircopan

AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry